+ 34 986 812 316

Schnekenburger group: Cancer Epigenetics.
Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg 9, rue Edward Steichen; L-2540 Luxembourg

Epigenetics, anti-cancer therapy, Histone deacetylase inhibitors, cell death mechanisms, cell signalling


Various solid and non-solid cancer and non-cancerous cell lines; healthy PBMCs; CD34+ from cord blood; Zebrafish


Cell related assays to investigate canonical and non-canonical cell death pathways, UV microscopy, FACS, western blotting, molecular biology for DNA and RNA (RT-PCR, real-time PCR), chromatin immunoprecipitation, HDAC assays, DNA methylation analysis (MSP, bisulfite sequencing, MSRA)

Collaborations outside COST

Gilbert Kirsch (UMR CNRS 7565 SRSMC, Université de Lorraine, 57070 Metz, France) Bernard Pirotte (Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines(CIRM), University of Liege, 4000 Liege, Belgium) Robert Kiss (Laboratoire de Cancerologie et de Toxicologie Experimentale, Faculté de Pharmacie, Université Libre de Bruxelles, 1050 Brussels, Belgium) Guy Bormans (Lab of Radiopharmacy, KU Leuven, Leuven, Belgium) Byung Woo Han (SNU-Harvard Neurovascular Protection Center, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Korea)

Short description of ongoing research projects

The main topics of our research activities are: - I. Identification of new epigenetic modulators exhibiting anticancer activities. - II. Investigation of mechanisms by which epigenetic modulators induce antitumor activities for preventive and therapeutic purposes. - III. Establishment of new therapeutic strategies against cancer using combination treatments with epigenetic-targeted and chemotherapeutic drugs.

  1. Schnekenburger M, Grandjenette C, Gelfi J, Karius T, Foliguet B, Dicato M, Diederich M. Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol. 2011 Feb 1 ; 81(3):364-78.
  2. Valente S, Liu Y, Schnekenburger M, Zwergel C, Cosconati S, Gros C, Tardugno M, Labella D, Florean C, Minden S, Hashimoto H, Chang Y, Zhang X, Kirsch G, Novellino E, Arimondo PB, Miele E, Ferretti E, Gulino A, Diederich M, Cheng X, Mai A. Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including cancer stem cells. J Med Chem. 2014 Feb 13;57(3):701-13.
  3. Seidel C, Schnekenburger M, Mazumder A, Teiten MH, Kirsch G, Dicato M, Diederich M. 4- Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer. Biochem Pharmacol. 2016 Jan 1;99:31-52.
  4. Florean C, Schnekenburger M, Lee JY, Kim KR, Mazumder A, Song S, Kim JM, Grandjenette C, Kim JG, Yoon AY, Dicato M, Kim KW, Christov C, Han BW, Proksch P, Diederich M. Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. Oncotarget. 2016 Mar 19.
  5. Schnekenburger M, Goffin E, Lee JY, Jang JY, Mazumder A, Ji S, Rogister B, Bouider N, Lefranc F, Miklos W, Mathieu V, De Tullio P, Kim KW, Dicato M, Berger W, Han BW, Kiss R, Pirotte B, Diederich M. Discovery and characterization of R/S-N-3-Cyanophenyl-N'-(6-tert- butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a new histone deacetylase Class III Inhibitor exerting antiproliferative activity against cancer cell lines. J Med Chem. 2017.
Other activities of potential interest to others

Cost UE